Autres langues Myriad Genetics, Inc.

Actions

MYGN

US62855J1043

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq 22:00:00 12/08/2026			Varia. 5j.	Varia. 1 janv.
3,230 ^USD	+0,31%		+2,54%	-47,48%

31/07	Transcript : Myriad Genetics, Inc., Q2 2026 Earnings Call, Jul 30, 2026
30/07	Myriad Genetics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

30/07	Myriad: Q2 Earnings Snapshot
30/07	Myriad Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/07	Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
30/07	Myriad Genetics, Inc. Reports Production Results for the Second Quarter and Six Months Ended June 30, 2026
30/07	Myriad Genetics Inc. Revises Earnings Guidance for the Full Year 2026
23/07	Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
21/07	Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
20/07	Burning Rock Biotech Limited and Myriad Genetics Announce Global Strategic Technology Licensing Partnership to Expand Hrd Testing Worldwide
02/07	Myriad Genetics Publishes Large-Scale Meta-Analysis Demonstrating Prognostic Performance of Prolaris Biopsy Test in Localized Prostate Cancer
02/07	New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
23/06	Myriad Genetics, Inc. Announces Resignation of Daniel M. Skovronsky from Director, Effective June 17, 2026
23/06	Myriad Genetics Expands Availability of Precise Mrd for Colorectal, Renal and Breast Cancers
23/06	Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
02/06	Myriad Genetics, Inc. Announces Appointment of Raj Jampa to Chief Technology Officer, Effective June 1, 2026
02/06	Myriad Genetics Names Raj Jampa as New Chief Technology Officer
27/05	Myriad Genetics Highlights Data Demonstrating Broad Clinical Utility of Precise Mrd Assay At 2026 Asco Annual Meeting
27/05	Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
26/05	Myriad Genetics to Launch Prolaris + AI Prostate Cancer Test
26/05	Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
26/05	Myriad Genetics Launches Prolaris Plus AI Test Combining Genomics And Digital Pathology Artificial Intelligence
15/05	Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
08/05	Myriad Genetics : to Participate in Upcoming Investor Healthcare Conferences
07/05	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
05/05	Myriad: Q1 Earnings Snapshot
05/05	Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business